Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site

Annals of Surgical Oncology

Volumn 18, Issue 13, 2011, Pages 3586-3592

  Prens, Sebastiaan P ^a   Van Der Ploeg, Augustinus P T ^a   Van Akkooi, Alexander C J ^a   Van Montfort, Cornelis A G M ^a   Van Geel, Albertus N ^a   De Wilt, Johannes H W ^b   Eggermont, Alexander M M ^a,c   Verhoef, Cornelis ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; HUMAN; INCIDENCE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; NECK DISSECTION; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR LOCALIZATION;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, UNKNOWN PRIMARY; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 82955233515     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1801-5     Document Type: Article

References (22)

1. DS Rigel J Russak R Friedman 2010 The evolution of melanoma diagnosis: 25 years beyond the ABCDs CA Cancer J Clin. 60 301 316 20671054 10.3322/caac.20074
2. CM Balch SJ Soong JE Gershenwald, et al. 2001 Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system J Clin Oncol. 19 3622 3634 11504744 1:STN:280:DC%2BD3MvlvV2ktA%3D%3D (Pubitemid 32786275)
3. AE Chang LH Karnell HR Menck 1998 The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society Cancer. 83 1664 1678 9781962 10.1002/(SICI)1097-0142(19981015)83: 8<1664::AID-CNCR23>3.0.CO;2-G 1:STN:280:DyaK1cvltlahsQ%3D%3D (Pubitemid 28465486)
4. CC Lee MB Faries LA Wanek DL Morton 2008 Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma J Clin Oncol. 26 535 541 18235114 10.1200/JCO.2007.14.0285 (Pubitemid 351264345)
5. JN Cormier Y Xing L Feng, et al. 2006 Metastatic melanoma to lymph nodes in patients with unknown primary sites Cancer. 106 2012 2020 16568458 10.1002/cncr.21835 (Pubitemid 43673218)
6. KA Katz E Jonasch FS Hodi, et al. 2005 Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute Melanoma Res. 15 77 82 15714125 10.1097/00008390-200502000-00013 (Pubitemid 40354478)
7. KK Anbari LM Schuchter LP Bucky, et al. 1997 Melanoma of unknown primary site: presentation, treatment, and prognosis-a single institution study. University of Pennsylvania Pigmented Lesion Study Group Cancer. 79 1816 1821 9129001 10.1002/(SICI)1097-0142(19970501)79:9<1816::AID-CNCR26>3.0.CO;2-# 1:STN:280:DyaK2s3nsFWjtQ%3D%3D (Pubitemid 27176366)
8. U Keilholz CJ Punt M Gore, et al. 2005 Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group J Clin Oncol. 23 6747 6755 16170182 10.1200/JCO.2005.03.202 1:CAS:528:DC%2BD2MXhtFWqsLfF (Pubitemid 46190270)
9. AM Eggermont S Suciu R MacKie, et al. 2005 Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial Lancet 366 9492 1189 1196 16198768 10.1016/S0140-6736(05)67482-X 1:CAS:528: DC%2BD2MXhtVGrsrbL (Pubitemid 41393597)
10. AM Eggermont S Suciu M Santinami, et al. 2008 Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial Lancet 372 9633 117 126 18620949 10.1016/S0140-6736(08)61033-8 1:CAS:528: DC%2BD1cXosVynurk%3D (Pubitemid 351952257)
11. T Ramirez-Montagut MJ Turk JD Wolchok, et al. 2003 Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity Oncogene. 22 3180 3187 12789294 10.1038/sj.onc.1206462 1:CAS:528:DC%2BD3sXkt12qu78%3D (Pubitemid 36713770)
12. G Konjevic K Mirjacic Martinovic A Vuletic N Babovic 2010 In-vitro IL-2 or IFN-alpha-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients Melanoma Res. 20 459 467 20938360 10.1097/CMR.0b013e32833e3286 1:CAS:528:DC%2BC3cXhtlOhs7vM
13. SJ Moschos HD Edington SR Land, et al. 2006 Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses J Clin Oncol. 24 3164 3171 16809739 10.1200/JCO.2005.05.2498 1:CAS:528:DC%2BD28XnslKhsL0%3D (Pubitemid 46638955)
14. DL Morton DW Ollila EC Hsueh, et al. 1999 Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma CA Cancer J Clin. 49 101 116 11198885 10.3322/canjclin.49.2.101 1:STN:280:DC%2BD3M7isV2gtQ%3D%3D (Pubitemid 29353924)
15. P Rutkowski ZI Nowecki W Dziewirski, et al. 2010 Melanoma without a detectable primary site with metastases to lymph nodes Dermatol Surg. 36 868 876 20482725 10.1111/j.1524-4725.2010.01562.x 1:CAS:528:DC%2BC3cXns1Snt74%3D
16. AC van Akkooi MG Bouwhuis AN van Geel, et al. 2007 Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma Eur J Surg Oncol. 33 102 108 17161577 10.1016/j.ejso.2006.10.032 (Pubitemid 46131880)
17. CM Balch JE Gershenwald SJ Soong, et al. 2010 Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases J Clin Oncol. 28 2452 2459 20368546 10.1200/JCO.2009.27.1627
18. TM Hughes RP A'Hern JM Thomas 2000 Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma Br J Surg. 87 892 901 10931025 10.1046/j.1365-2168.2000.01439.x 1:STN:280: DC%2BD3cvgtFymtw%3D%3D (Pubitemid 30487692)
19. JE Gershenwald SJ Soong CM Balch 2010 2010 TNM staging system for cutaneous melanoma...and beyond Ann Surg Oncol 17 1475 1477 20300965 10.1245/s10434-010-0986-3
20. DJ Grunhagen AM Eggermont AN van Geel, et al. 2005 Prognostic factors after cervical lymph node dissection for cutaneous melanoma metastases Melanoma Res. 15 179 184 15917699 10.1097/00008390-200506000-00006 (Pubitemid 40839465)
21. ER Koomen E de Vries LC van Kempen, et al. 2010 Epidemiology of extracutaneous melanoma in the Netherlands Cancer Epidemiol Biomarkers Prev. 19 1453 1459 20501769 10.1158/1055-9965.EPI-09-1267
22. N Bories S Dalle S Debarbieux, et al. 2008 Dermoscopy of fully regressive cutaneous melanoma Br J Dermatol. 158 1224 1229 18341656 10.1111/j.1365-2133. 2008.08501.x 1:STN:280:DC%2BD1czitFOltw%3D%3D (Pubitemid 351692853)